• Niagen Bioscience is targeting an estimated $500 million NAD+ infusion and injection market through its Niagen Plus portfolio.
• Niagen IV is available in more than 1,700 clinics nationwide.
• A new ready-to-inject liquid Niagen product is available through a clinician-directed telehealth platform under Niagen Plus.
• Expansion plans include partnerships with large skincare companies and development of therapies for rare genetic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.